The ABCs of ADCs: manufacturing ultra-high potent active ingredients

Published: 17-Jan-2025

Senior Technical Manager at Sterling Pharma Solutions, Matt Miklas, presents a pragmatic approach to the safe and cost-effective production of highly potent pharmaceutical molecules, including antibody-drug conjugate (ADC) payloads

You need to be a subscriber to read this article.
Click here to find out more.

The highly potent API (HPAPI) sector is one of the fastest growing areas in the pharmaceutical industry; the annual revenue from these drugs is expected to reach a value of $40 billion in 2025.1

More than a quarter of drugs on the market today are classed as highly potent and the contract manufacturing market for HPAPIs is expected to grow at a CAGR of 10.1% through to 2027.2,3

Although the market for HPAPIs is largely in oncology, they also used in a range of applications including asthma, diabetes and cardiovascular diseases.

Nearly a third of new drug approvals during the past few years have been for cancer and 60% of oncology drugs currently in development involve highly potent ingredients, emphasising the importance of the sector’s ability to handle and manufacture these products.1,4  

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like